Johns Hopkins Startup Neuraly Plans Phase 1 Parkinson’s Trial

(July 23, 2018) – A new startup from Johns Hopkins has launched with $36 million in financing in the pursuit of disease-modifying agents for Parkinson’s disease and other neurodegenerative disorders. The company’s pipeline is built around NLY01, a long-acting glucagon-like peptide-1 receptor agonist that penetrates the brain and has shown promise as a neuroprotective agent. Read more…